Methotrexate Sustained-Release Implant for PVR Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack preventive measures for proliferative vitreoretinopathy (PVR) and epiretinal membranes (ERM), which are common complications following retinal detachment surgery, leading to potential vision loss and the need for additional surgeries.
Innovation Solution
A sustained-release formulation of methotrexate, administered intravitreally over at least a three-month period, either through multiple injections or an implanted device, to reduce the risk of PVR or ERM development, particularly in patients undergoing high-risk ocular surgical procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple intravitreal injections of methotrexate are administered over a three-month period, then the risk of PVR and ERM is reduced, but the complexity of treatment increases
Solution Approach 1:
The sustained-release implant is installed during the initial retinal detachment surgery, performing preventive action before PVR and ERM can develop. This eliminates the need for multiple follow-up injections by delivering methotrexate continuously over 3-6 months, thereby reducing treatment complexity while maintaining high reliability in preventing proliferative complications.
2Duration of action of moving object
If sustained-release formulation of methotrexate is used, then therapeutic levels are maintained longer, but the device complexity increases
Solution Approach 1:
The patent utilizes biodegradable polymer matrices with controlled degradation rates to maintain therapeutic methotrexate levels over extended periods. By adjusting polymer composition and crosslinking density, the release kinetics are optimized to provide sustained delivery for 3-6 months, achieving long duration of action without requiring complex external delivery systems.
3Reliability
If methotrexate is administered to prevent PVR and ERM, then visual outcomes are improved, but the risk of side effects increases
Solution Approach 1:
The sustained-release implant delivers methotrexate directly to the vitreous cavity at the site where PVR and ERM develop, achieving high local concentrations while minimizing systemic exposure. This localized delivery approach enhances therapeutic efficacy for preventing proliferative complications while reducing the risk of systemic side effects such as bone marrow suppression and gastrointestinal toxicity.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.